Lipigon Pharmaceuticals AB (publ) (FRA:9RP)
Germany · Delayed Price · Currency is EUR 0.0038
+0.0002 (5.56%)
At close: Nov 28, 2025
FRA:9RP Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| 0.88 | 10.29 | 16.41 | - | 2.21 | 4.01 | Upgrade | |
Revenue Growth (YoY) | -90.71% | -37.30% | - | - | -44.86% | 130.19% | Upgrade |
Cost of Revenue | 28.01 | 28.7 | 21.52 | 31.66 | 38.25 | 8.73 | Upgrade |
Gross Profit | -27.12 | -18.41 | -5.12 | -31.66 | -36.04 | -4.72 | Upgrade |
Selling, General & Admin | 9.64 | 7.81 | 7.44 | 6.07 | 5.44 | 3.36 | Upgrade |
Other Operating Expenses | 0.56 | 0.64 | 0.87 | 0.39 | 0.69 | -0.26 | Upgrade |
Operating Expenses | 10.3 | 8.51 | 8.33 | 6.48 | 6.12 | 3.1 | Upgrade |
Operating Income | -37.42 | -26.93 | -13.45 | -38.13 | -42.16 | -7.82 | Upgrade |
Interest Expense | -0.27 | -0.06 | -0 | - | -0.01 | -0 | Upgrade |
Interest & Investment Income | 0.38 | 0.38 | 0.25 | 0.04 | 0.08 | 0.01 | Upgrade |
Currency Exchange Gain (Loss) | 1.35 | 1.35 | 1.07 | 0.39 | - | - | Upgrade |
Other Non Operating Income (Expenses) | - | - | 0 | - | 0.97 | - | Upgrade |
EBT Excluding Unusual Items | -35.97 | -25.26 | -12.13 | -37.71 | -41.11 | -7.82 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.25 | Upgrade |
Pretax Income | -35.97 | -25.26 | -12.13 | -37.71 | -41.11 | -8.07 | Upgrade |
Net Income | -35.97 | -25.26 | -12.13 | -37.71 | -41.11 | -8.07 | Upgrade |
Net Income to Common | -35.97 | -25.26 | -12.13 | -37.71 | -41.11 | -8.07 | Upgrade |
Shares Outstanding (Basic) | - | 138 | 64 | 15 | 9 | 4 | Upgrade |
Shares Outstanding (Diluted) | - | 138 | 64 | 15 | 9 | 4 | Upgrade |
Shares Change (YoY) | - | 115.86% | 336.30% | 63.10% | 104.09% | 1.84% | Upgrade |
EPS (Basic) | - | -0.18 | -0.19 | -2.57 | -4.56 | -1.83 | Upgrade |
EPS (Diluted) | - | -0.18 | -0.19 | -2.57 | -4.56 | -1.83 | Upgrade |
Free Cash Flow | -28.44 | -25.02 | -14.32 | -37.47 | -35.42 | -8.63 | Upgrade |
Free Cash Flow Per Share | - | -0.18 | -0.22 | -2.55 | -3.93 | -1.95 | Upgrade |
Gross Margin | - | -179.00% | -31.19% | - | - | -117.73% | Upgrade |
Operating Margin | -4247.90% | -261.74% | -81.95% | - | -1906.83% | -195.11% | Upgrade |
Profit Margin | -4082.75% | -245.59% | -73.92% | - | -1859.48% | -201.20% | Upgrade |
Free Cash Flow Margin | -3227.58% | -243.18% | -87.27% | - | -1601.94% | -215.09% | Upgrade |
EBITDA | -37.32 | -26.87 | -13.42 | -38.11 | -42.14 | - | Upgrade |
EBITDA Margin | - | -261.16% | -81.81% | - | - | - | Upgrade |
D&A For EBITDA | 0.1 | 0.06 | 0.02 | 0.02 | 0.02 | - | Upgrade |
EBIT | -37.42 | -26.93 | -13.45 | -38.13 | -42.16 | -7.82 | Upgrade |
EBIT Margin | - | -261.74% | -81.95% | - | - | -195.11% | Upgrade |
Revenue as Reported | 2.23 | 11.64 | 17.48 | 0.39 | 3.18 | 4.28 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.